Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data

被引：0
|
作者：
Jorge Nieva
Karen L. Reckamp
Danielle Potter
Aliki Taylor
Ping Sun
机构：
[1] University of Southern California,Department of Medicine
[2] Norris Comprehensive Cancer Center,Department of Medicine
[3] Cedars Sinai Medical Center,Global Epidemiology, Oncology Business Unit, Global Medical Affairs
[4] AstraZeneca,Real World Science and Digital
[5] AstraZeneca,CancerLinQ LLC
[6] American Society of Clinical Oncology,undefined
来源：
Drugs - Real World Outcomes | 2022年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：333 / 345
页数：12
相关论文
共 50 条
  • [1] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Nieva, Jorge
    Reckamp, Karen L.
    Potter, Danielle
    Taylor, Aliki
    Sun, Ping
    [J]. DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 333 - 345
  • [2] US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
    Nieva, J.
    Reckamp, K.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S399
  • [3] US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment
    Reckamp, K.
    Nieva, J.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S402 - S402
  • [4] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
  • [5] Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study
    Tian, Panwen
    Wu, Lin
    Zhou, Chengzhi
    Tan, Jie
    Wang, Ke
    Luo, Feng
    Liu, Yongmei
    Guo, Yubiao
    Li, Yinyin
    Liu, Zhe
    Gong, Youling
    Wang, Yongsheng
    Li, Weimin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis
    Liu, Sangtian
    Liang, Wenhua
    He, Jianxing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [8] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [9] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [10] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    [J]. TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
12345